Nancy L. Weigel

Nancy L. Weigel

Auto-generated profile, based on publicly available information

Nancy L. Weigel

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2006 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
IAIrina Agoulnik
Irina Agoulnik
NWNancy L. Weigel
Nancy L. Weigel

10 November 2009 in BioFactors
Verified
Journal Article
Closed access
PDF file
RWRobert D. Ward
Robert D. Ward
NWNancy L. Weigel
Nancy L. Weigel

10 September 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ASAyesha A. Shafi
Ayesha A. Shafi
VPVasanta Putluri
Vasanta Putluri
JAJames M. Arnold
James M. Arnold
ETEfrosini Tsouko
Efrosini Tsouko
SMSuman Maity
Suman Maity
NWNancy L. Weigel
Nancy L. Weigel
Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells

1 September 2014 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
WKWilliam C. Krause
William C. Krause
ASAyesha A. Shafi
Ayesha A. Shafi
MNManjula Nakka
Manjula Nakka
NWNancy L. Weigel
Nancy L. Weigel

22 January 2009 in Endocrinology
Verified
Journal Article
Open access
PDF file
JRJoyAnn N. Phillips Rohan
JoyAnn N. Phillips Rohan
NWNancy L. Weigel
Nancy L. Weigel
There is an inverse correlation between exposure to sunlight (the major source of vitamin D) and the risk for prostate cancer, the most common noncutaneous cancer and second most common cause of death from cancer in American men. The active metabolite of vitamin D, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] acting through the vitamin D receptor decreases prostate cancer cell growth and invasiveness. The precise mechanisms by which 1,25(OH)2D3 inhibits growth in prostate cancer have not been fully elucidated. Treatment with 1,25(OH)2D3 causes an accumulation in the G0/G1 phase of the cell cycle in several prostate cancer cell lines. One potential target known to regulate the G0/G1 to S phase transition is c-Myc, a transcription factor whose overexpression is associated with a number of cancers including prostate cancer. We find that 1,25(OH)2D3 reduces c-Myc expression in multiple prostate epithelial cell lines, including C4-2 cells, an androgen-independent prostate cancer cell line. Reducing c-Myc expression to the levels observed after 1,25(OH)2D3 treatment resulted in a comparable decrease in proliferation and G1 accumulation demonstrating that down-regulation of c-Myc is a major component in the growth-inhibitory actions of 1,25(OH)2D3. Treatment with 1,25(OH)2D3 resulted in a 50% decrease in c-Myc mRNA but a much more extensive reduction in c-Myc protein. Treatment with 1,25(OH)2D3 decreased c-Myc stability by increasing the proportion of c-Myc phosphorylated on T58, a glycogen synthase kinase-3β site that serves as a signal for ubiquitin-mediated proteolysis. Thus, 1,25(OH)2D3 reduces both c-Myc mRNA levels and c-Myc protein stability to inhibit growth of prostate cancer cells.

1 October 2013 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
LTLindsey S. Treviño
Lindsey S. Treviño
NWNancy L. Weigel
Nancy L. Weigel